Related Experiment Video

Updated: May 1, 2026

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding
10:43

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding

Published on: June 27, 2014

20.6K

SeDeM and Powder flow tools-assisted design of solid SMEDDS of luliconazole for antifungal therapy

Sharad S Kale1, Deepak Kulkarni2, Anuja G Magar3

  • 1Department of Physiology, School of Medicine, Pusan National University, Yangsan, Republic of Korea.

Therapeutic Delivery
|February 28, 2026
PubMed
Abstract

Keywords:
Neusilin US2SMEDDSantifungalluliconazolewheat straw

More Related Videos

Microfluidic Tools for Probing Fungal-Microbial Interactions at the Cellular Level08:19

Microfluidic Tools for Probing Fungal-Microbial Interactions at the Cellular Level

Published on: June 23, 2022

4.4K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.1K

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119